Veracyte Projects 10%-13% Revenue Growth for 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 11 2026
0mins
Source: Businesswire
- Financial Outlook: Veracyte anticipates total revenue for 2025 to reach between $570 million and $582 million, reflecting a 10% to 13% growth compared to 2024, which will further solidify its leadership in the cancer diagnostics market.
- Testing Revenue Growth: The company expects testing revenue to grow by 14% to 16% in 2026, amounting to between $559 million and $569 million, indicating strong demand and market potential for its core business.
- Adjusted EBITDA Margin: Veracyte projects an adjusted EBITDA margin exceeding 25% for 2025, demonstrating effective strategies in cost control and profitability enhancement.
- Product Launch Plans: The company plans to launch the Prosigna and TrueMRD platforms in 2026, which are expected to further expand patient reach and improve financial performance, showcasing its commitment to continuous innovation.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like VCYT with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on VCYT
Wall Street analysts forecast VCYT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VCYT is 46.14 USD with a low forecast of 43.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 38.480
Low
43.00
Averages
46.14
High
50.00
Current: 38.480
Low
43.00
Averages
46.14
High
50.00
About VCYT
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Elekta EKTAY's Evo CT-Linac Receives FDA Clearance, Enhancing Personalized Radiation Therapy
- FDA Approval Milestone: Elekta's Evo CT-Linac has received 510(k) clearance from the FDA, enabling its availability in the U.S. market, marking a critical step in the company's expansion in radiation oncology and expected to drive the adoption of personalized radiation therapy.
- Market Growth Potential: The AI-driven imaging capabilities of Elekta Evo enhance the visualization of tumors and organs-at-risk, which is anticipated to drive revenue growth and deepen customer relationships, further solidifying the company's position in the competitive radiation therapy market.
- Operational Efficiency Improvement: Elekta is implementing a new operating model expected to generate annual cost savings of at least SEK 500 million, aimed at accelerating product development and improving overall operational efficiency, thereby enhancing customer service quality.
- Order Review Impact: Elekta has completed a second-level review of orders, resulting in the cancellation of approximately SEK 2.197 billion in orders to improve predictability and support long-term profitability, reflecting the company's stringent control over order criteria.
Continue Reading
Abbott Laboratories (ABT) Forecasts Q4 2025 Revenue of $11.79 Billion, Up 7.5%
- Earnings Forecast: Abbott anticipates Q4 2025 EPS of $1.50, reflecting an 11.9% year-over-year increase, indicating strong performance in its medical devices and nutrition segments.
- Diagnostics Growth: Despite revenue impacts from procurement programs in China, Abbott's diagnostics segment is expected to grow 0.8% year-over-year, demonstrating sustained global demand for routine diagnostic testing.
- Medical Device Sales Surge: The medical devices segment is projected to see a 12.5% year-over-year revenue increase, driven by diabetes care and cardiac rhythm management products, particularly following the launch and FDA approval of the Volt PFA catheter.
- Nutrition Innovation: Abbott's launch of low-sugar Glucerna and the Ensure Max Protein line is expected to contribute to a 3.3% year-over-year revenue growth in the nutrition segment, further solidifying its market position.
Continue Reading